INDIVIDUAL FELLOWSHIPS

Project n°: 274569

Project Acronym: BRCA2-RAD51

Project Full Name: The use of fragment-based drug discovery to develop novel small molecules that modulate the BRCA2-RAD51 interaction for the treatment of cancer

Marie Curie Actions

IEF-IOF-IIF- IIFR -Final Report

Figures 1A, 1B and 2 in Final Publishable Summary

Period covered: from 01/03/2011 **to** 28/02/2013

Period number:

Start date of project: 1st March 2011

Project beneficiary name: Dr. Chiara Rosa Valenzano

Project beneficiary organisation name: University of Cambridge

Date of preparation: 01/03/2013

Date of submission (SESAM): __5 April 2013_____

Duration: 24 months

Version: _____

FIGURE 1 A AND FIGURE 1 B



Figure 1 A. Human RAD51 has structural and functional homologs in every species. In cells RAD51 is oligomeric; each monomer includes an N-terminal domain connected with the C-terminal catalytic domain by a peptide linker which bears the FxxA oligomerisation motif. **B.** Crystal structure of RAD51-BRC4 complex (PB ID: 1N0W) showing the two main regions of interaction.

FIGURE 2



Figure 2. Model of binding of Velcro specific stapled peptide to oligomeric RAD51.